{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:07:52Z","timestamp":1788404872491,"version":"build-2803163510"},"reference-count":39,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,8,15]],"date-time":"2007-08-15T00:00:00Z","timestamp":1187136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>\u2022\u2002The occurrence of central nervous system\u2010related adverse effects has been apparently related to the absorption rate of carbamazepine (CBZ).<\/jats:p>\n                    <jats:p>\u2022\u2002However, the differing absorption rate metrics of four carbamazepine formulations in a bioequivalence study were unclearly associated with the incidence of adverse effects.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>\u2022\u2002The relationship between the incidence of most neurological adverse effects and the absorption rate of CBZ was quantitatively established.<\/jats:p>\n                    <jats:p>\u2022\u2002A mixed\u2010effect PK\u2013PD model demonstrated the rapid development of acute tolerance to these effects.<\/jats:p>\n                    <jats:p>\u2022\u2002Characterization of PD and PK\u2013PD sensitivities showed that clinically significant differences in toxicity can exist between bioequivalent CBZ formulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>AIMS<\/jats:title>\n                    <jats:p>To assess whether, using the current regulatory criteria, therapeutically important differences can exist between bioequivalent carbamazepine (CBZ) tablets. A secondary goal was to demonstrate quantitatively the relationship between the risk of neurological adverse effects to orally ingested CBZ and the rate of absorption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Results of a bioequivalence study by Olling\n                      <jats:italic>et\u2003al.<\/jats:italic>\n                      (Biopharm Drug Dispos 1999; 20: 19\u201328) were reanalysed. Following an exploratory data analysis step, a mixed\u2010effect pharmacokinetic\u2013pharmacodynamic (PK\u2013PD) model was built to describe the dependence of adverse events on the CBZ concentration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Rapid development of tolerance was demonstrated for most neurological adverse effects, with a characteristic half\u2010life of 02.29\u2003h and an initial EC50 of 2.33\u2003mg\u2003l\n                      <jats:sup>\u22121<\/jats:sup>\n                      . The resulting tolerance PK\u2013PD model was characterized further using the tools and terminology of sensitivity analysis. It was demonstrated that the maximum concentration (\n                      <jats:italic>C<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      ) exhibits poor PK and PD sensitivities, and that clinically significant differences can exist between formulations which otherwise comply with the bioequivalence requirements. In contrast, another PK metric, the partial AUC, was a much better marker of the early neurological adverse events observable during the absorption phase of the drug.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      In clinical and regulatory considerations, the development of acute tolerance for adverse effects of CBZ must be taken into account. Partial AUC reflects more sensitively the risk of adverse events than\n                      <jats:italic>C<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      . Instead of the current trend of tightening of the bioequivalence criteria for narrow therapeutic index drugs, the use of alternative, more sensitive PK metrics is proposed.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1365-2125.2007.02984.x","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T00:33:12Z","timestamp":1187310792000},"page":"110-122","source":"Crossref","is-referenced-by-count":31,"title":["Exposure\u2013response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets"],"prefix":"10.1111","volume":"65","author":[{"given":"Laszlo","family":"Tothfalusi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szilvia","family":"Speidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Endrenyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,10,22]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200023030-00001"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(96)80013-6"},{"key":"e_1_2_7_4_2","first-page":"226","article-title":"Bioavailability and central side effects of different carbamazepine tablets","volume":"23","author":"Neuvonen PJ.","year":"1985","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_7_5_2","first-page":"284","article-title":"Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations","volume":"42","author":"Wolf P","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1980.tb04081.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1984.tb03446.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00561742"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1978.tb02270.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011929300613"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-081X(199901)20:1<19::AID-BDD152>3.0.CO;2-Q"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050443"},{"key":"e_1_2_7_13_2","first-page":"394","article-title":"Cmax\/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence","volume":"29","author":"Endrenyi L","year":"1991","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016237826520"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015842425553"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011916113082"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016215116835"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0928-0987(03)00064-2"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-21706-2"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-0318-1"},{"key":"e_1_2_7_21_2","doi-asserted-by":"crossref","DOI":"10.1002\/0471722146","volume-title":"Applied Logistic Regression.","author":"Hosner D","year":"2000"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(00)00077-2"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-005-0074-7"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj070351"},{"key":"e_1_2_7_25_2","first-page":"37","volume-title":"Frontiers of Clinical Neuroscience","author":"Dodrill C.","year":"1991"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026053386962"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(99)00083-4"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2004.00291.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/02698811030173007"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.6.1170"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199802000-00010"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01414.x"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70132-3"},{"key":"e_1_2_7_34_2","volume-title":"Guidance for Industry. Bioequivalence Requirements: Critical Dose Drugs.","year":"2006"},{"key":"e_1_2_7_35_2","volume-title":"Bioavailability of Oral Dosage Formulations for Systemic Effects.","year":"1992"},{"key":"e_1_2_7_36_2","unstructured":"The European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products (CPMP).Note for Guidance on the Investigation of Bioavailability and Bioequivalence. CPMP\/EWP\/QWP\/1401\/98 London 26 July 2001. Available athttp:\/\/www.emea.europa.eu\/pdfs\/human\/ewp\/140198en.pdfLast accessed 27 March 2007."},{"key":"e_1_2_7_37_2","volume-title":"Bioequivalence and Labelling of Medicinal Products with Regard to Generic Substitution.","year":"2006"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016061013606"},{"key":"e_1_2_7_39_2","unstructured":"Food and Drug Administration.Guidance for Industry: Bioavailability and Bioequivalence for Orally Administered Drug Products\u2014General Considerations.Revision 1. Rockville MD.2003. Available athttp:\/\/www.fda.gov\/cder\/guidance\/5356fnl.pdfLast accessed 27 March 2007."},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2003.05.002"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2007.02984.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2007.02984.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T11:34:12Z","timestamp":1697369652000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2007.02984.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,22]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1111\/j.1365-2125.2007.02984.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02984.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,22]]}}}